| Theme | The consideration of polypharmacy in dialysis patients | |
|---|---|---|
| Title | Management of polypharmacy in dialysis patients -- from the physician's viewpoint | |
| Publish Date | 2017/04 | |
| Author | Kyoko Ito | Kidney Disease and Dialysis Center, Hidaka-kai |
| Author | Takaaki Tsutsui | Kidney Disease and Dialysis Center, Hidaka-kai |
| Author | Nobuo Nagano | Kidney Disease and Dialysis Center, Hidaka-kai |
| [ Summary ] | Dialysis patients have a greater risk for the occurrence of adverse events caused by drug-drug interactions under polypharmacy. In addition, polypharmacy, including injected drugs, of dialysis patients should be recognized. There is, however, currently neither a deprescribing protocol nor evidence of efficacy of deprescribing on clinical outcomes in dialysis patients. Because there are many barriers to deprescribing, physicians should pay attention to avoid several pitfalls that lead to polypharmacy in medical practice. There is a critical need to establish uniform standards for identifying inappropriate medications and deprescribing in dialysis patients. | |